Skip to content

In Vivo Glycocalyx as Predictor of Complications After Cardiac Surgery

Glycocalyx as Predictor of Complications After Cardiac Surgery

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04643535
Acronym
GLYPOCS
Enrollment
130
Registered
2020-11-25
Start date
2020-11-30
Completion date
2025-12-30
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Endothelial Dysfunction, Surgery

Brief summary

Cardiac surgery has been described as altering endothelium structure and function, notably because of the use of cardiac-pulmonary bypass (CPB). Among the endothelial structure, glycocalyx, the thin layer recovering the endothelial surface, may be altered by the inflammatory process and probably the modification of flow during CPB. Endothelial and glycocalyx integrity are essential for vascular function and glycocalyx destruction is associated with organ failure and mortality. On the other hand, a chronic alteration of glycocalyx is observed in many diseases such as diabetes, hypertension or chronic kidney failure, all pathologies frequently observed in patients benefiting grom cardiac surgery. Thus the preoperative alteration of glycocalyx may be associated with postoperative organ failure.

Interventions

None listed

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients benefiting from a cardiac surgery with cardio-pulmonary bypass

Exclusion criteria

* impossibility to carry out the measurement by glycocheck device * refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
association between preoperative sublingual glycocalyx thickness (glycocheck device) and major postoperative complications48 hoursoccurence within 48 postoperative hours of at least one item among: * vasoplegic shock * cardiogenic shock * prolonged mechanical ventilation * acute kidney failure * Death

Secondary

MeasureTime frameDescription
association between preoperative sublingual glycocalyx thickness (glycocheck device) and death28 daysdeath from any causes
association between preoperative sublingual glycocalyx thickness (glycocheck device) and cardiac arrythmia28 daysatrial or ventricular arrythmia
association between preoperative sublingual glycocalyx thickness (glycocheck device) and Cerebral stroke28 daysischemic of hemorrhagic etiology
association between preoperative sublingual glycocalyx thickness (glycocheck device) and cognitive dysfunction28 daysdelirium or alteration of cognitive status
association between preoperative sublingual glycocalyx thickness (glycocheck device) and myocardial ischemia28 daysoccurence of ischemia: new Q wave, new occlusion of a coronary arteria, elevated troponinemia with a new dysfunction of at least one myocardial segment
association between preoperative sublingual glycocalyx thickness (glycocheck device) and acute respiratory failure28 daysneed for at least 5L/min of oxygen or non invasive ventilation of reintubation
association between preoperative sublingual glycocalyx thickness (glycocheck device) and sepsis28 daysnew sepsis condition as defined by SEPSIS-3 definition

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026